RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $38.
RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $38.